Skip to main content
. 2022 Jun 15;3(5):394–409. doi: 10.1158/2643-3230.BCD-21-0207

Figure 6.

Figure 6.

Single-cell RNA-seq reveals the universal presence of MHCII-low cells at diagnosis displaying an aberrant expression of the TF tetrad. A, scRNA-seq of AML cells obtained at initial presentation and relapse after alloSCT (patient 452198) or chemotherapy (all other patients). Data were downloaded from ref. (28) and clustered according to their genome-wide expression patterns using t-SNE. Cells from initial presentation and relapse are plotted together and highlighted according to the relapse status and MHCII expression, indicating the universal presence of MHCII-low cells (aggregate MHCII counts <300) in all patients at the time of initial presentation. B, Differences in the tetrad TF expression in the MHCII-low versus MHCII–high cells at the time of initial presentation. Asterisks indicate P values calculated by a two-tailed t test; **, P ≤ 0.01; ***, P ≤ 0.001; n.s., P > 0.05. MEIS1 was not expressed in sample 869586.